ADAM8 is expressed widely in breast cancer and predicts poor outcome in hormone receptor positive, HER-2 negative patients

Table 2 ADAM8 is expressed in a third of all breast cancers

ADAM8 level	Subtype	ALL			TNBC			HR−/HER2+			HR+/HER2−			HR+/HER2+
ADAM8 level	H-score	n	%		n	%		n	%		n	%		n	%
Negative	0	324	66.1		39	63.9		16	72.7		201	66.8		19	67.9
Low	50–150	51	10.4	33.9	7	11.5	36.1	0	0.0	27.3	34	11.3	33.2	1	3.6	32.1
High	200–300	115	23.5	33.9	15	24.6	36.1	6	27.3	27.3	66	21.9	33.2	8	28.6	32.1
	Total	490			61			22			301			28

The results of the ADP2 IHC analysis for ADAM8 in the breast cancer TMAs are summarized in a table format. The number (n) of tumors with Negative, Low or High ADAM8 expression levels, defined as H-scores of 0, 50–150 and 200–300, respectively, as well as corresponding percentages (%), are presented for the 490 total patient samples analyzed (ALL), as well as for each individual breast cancer subtype

ISSN: 1475-2867